MIAMI – (COMMERCIAL THREAD) – Heru, a medical technology company at Bascom Palmer Eye Institute that is developing a next-generation AI platform for diagnosing and augmenting vision, today announces its Class I list to the United States Food and Drug Administration (FDA) for its cloud-based augmented / virtual system the first reality platform diagnostic application for visual field examinations. Additionally, it closed an initial investment round of $ 2.7 million on June 15, 2020. The funding facilitates the completion of ongoing clinical trials for FDA clearance of the AI platform. laptop from Heru and subsequent marketing efforts..
According to JAMA Ophthalmology, more than 50 million patients in the United States suffer from visual field defects and strabismus due to glaucoma, stroke, age-related macular degeneration (AMD), diabetes and retinitis pigmentosa (450 million worldwide). Heru’s practical, accurate and validated AI software platform is uniquely positioned to enable exponential access and scale for critical eye health diagnostics, screening and visual augmentation of these patients.
“Gone are the days when bulky, cumbersome devices occupy examination rooms and medical grade furniture. Heru’s modern approach to diagnostics enables eyecare professionals to deploy lightweight cloud technology both virtually and in person, saving time and space while maintaining clinical standards of care, ”said Eduardo C. Alfonso, MD, professor and president Bascom Palmer Eye Institute.
Heru’s AI platform was developed by top minds in ophthalmology at the Bascom Palmer Eye Institute to alleviate critical bottlenecks and gaps in current patient care. Most importantly, the platform offers a cost effective scale to reach every patient in need of care.
The funding was led by Maurice R. Ferre, MD, Frederic H. Moll, MD, and a consortium of investors with extensive experience in the development, launch and scale-up of leading medical technologies.
“As a cloud-based software technology, Heru’s applications can reach healthcare providers instantly, in any setting, ”explains Ferre. “Now more than ever, it’s important that we harness cutting-edge technology to help patients diagnose and manage their vision health.
The company was founded in 2018 and is led by Mohamed Abou Shousha, MD, FRCS, PhD., Expert in diagnostics and vision augmentation, associate professor of clinical ophthalmology, electrical and computer engineering and biomedical engineering at Bascom Palmer Eye Institute, and Director of the AI and Computer Augmented Vision Laboratory.
In addition, John T. Trefethen has been appointed Director of Marketing. Trefethen has over twenty years of marketing and management experience in advanced ophthalmic technologies. Most recently, he led global marketing and product design for Topcon Healthcare, where he successfully rebranded the global device maker and launched the company’s entry into the eye telehealth market.
“The time is right,” said John Trefethen. “Healthcare technology has changed. We are experiencing a fundamental shift from physical devices to the software that controls them. We must evolve to meet the growing need for patient care. ”
About the company
Heru (www.SeeHeru.com) is originally a spin-off company of the Bascom Palmer Eye Institute at the University of Miami, ranked number one in the world as a leading hospital for ophthalmology (US News and World Report). Heru has developed patented AI-powered autonomous vision enhancement and diagnostic software for the best commercially available AR / VR headsets. The technology, including patents, patent applications, anonymized clinical data, and software, has been licensed exclusively to Heru from the University of Miami.
Heru’s platform is the only solution capable of autonomously diagnosing vision defects and tailoring individual vision enhancement based on the user’s unique vision defects. Heru’s solution involves cloud-based infrastructure, AI, web portals, and applications. There is no need for dedicated examination rooms; technicians and patients can perform tests in any environment (clinic, pharmacy, home), increasingly critical in today’s environment.